Samsung Biologics is committed to delivering solid financial results and sustainable business leadership through the maintenance of high standards of responsibility and ethics. Effective governance is critical for us to build a collaborative environment between management and employees, fulfill our responsibilities to clients, and create long-term value for shareholders.
- 000,000KRW
- 0,000
- (0.00%)
-
Volume
000,000
-
Today's open
₩000,000
-
High
₩000,000
-
Low
₩000,000
-
Previous Close
₩000,000
Latest Quarter Results
-
Latest News
-
-
Press Releases
2026.11.05
Samsung Biologics Publishes Definitive End Result for PolyPeptide Tender Offer with 97.99% Participation Rate
-
Press Releases
2026.11.04
Samsung Biologics Achieves ‘Negligible Risk’ Rating in Sustainalytics ESG Assessment
-
Media Focus
2026.11.04
From Static Capacity to Adaptive Networks: Building Resilience into Biologics Supply
-
Press Releases
2026.11.02
Samsung Biologics Publishes Provisional End Result for PolyPeptide Tender Offer with 97.99% Participation Rate
-
Press Releases
2026.11.05